Battling Bioavailability? Find Your Solubility Solution at BAC 2013!

It is a well-established principal that the most promising API, monoclonal antibody​ or therapeutic peptide​ can only be turned into an effective and marketable drug if formulated in such a way that it reaches the blood stream and is bioavailable​.

But, while this characteristic – bioavailability​ – has been the focus of scientists, researchers​ and process developers’​ efforts for years, finding the solution that gives a particular drug the desired profile is still a major headache for pharmaceutical firms.

Our free to attend online event​ will examine these challenges which are likely to become an increasingly common experience for drug development teams as pipelines​ fill with candidates based on biopharmaceutics classification system​ (BCS) class II​ and IV compounds​.

Generics too​

These difficulties are not limited to firms developing new drugs as generic drugmakers also face their own bioavailability challenges​.

Strict regulatory requirements on bioequivalence testing​ mean more trials, more analysis and more formulation development work, all of which increase cost and length of time it takes to bring a non-branded product to market.

Similarly, biopharmaceutical firms​ hoping to develop oral delivery​ alternatives for injectable biologics​ will also need to work out how to ensure that their products are bioavailable, safe and effective.

Programme ​

Our editorial webinar programme this year will be kicked off by Frost & Sullivan (F&S) analyst Deepika Pramod Chopda​ who will give an overview of Bioavailability in a market context and examine the current areas of demand and solutions on offer.

We’ll also hear from scientists at Hoffman La Roche​ and Bristol Myers Squibb​ who will set out the Big Pharma approach to Bioavailability Challenges and share their expertise on this complex and fascinating subject.

Attendees will have the chance to quiz our experts in the Q&A sessions that follow each webinar.

Leading suppliers​

In addition to our editorial programme we will also host presentations from some of the leading suppliers and services companies working in the field of bioavailability enhancement to give you a chance to hear about the latest scientific developments and technology solutions.